CVE:RVV Revive Therapeutics (RVV) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free RVV Stock Alerts C$0.08 +0.01 (+14.29%) (As of 07/22/2019) Add Compare Share Share Today's RangeC$0.08▼C$0.0950-Day RangeC$0.08▼C$0.0852-Week RangeC$0.07▼C$0.25Volume212,852 shsAverage Volume93,085 shsMarket CapitalizationC$5.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Revive Therapeutics alerts: Email Address Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Revive Therapeutics Stock (CVE:RVV)Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.Read More RVV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVV Stock News HeadlinesApril 23, 2024 | tmcnet.comRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVIDApril 18, 2024 | markets.businessinsider.comRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic ProductApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 27, 2024 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDMarch 27, 2024 | finance.yahoo.comRevive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDMarch 19, 2024 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDMarch 19, 2024 | markets.businessinsider.comRevive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDMarch 12, 2024 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics Provides Corporate UpdateApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 12, 2024 | financialpost.comRevive Therapeutics Provides Corporate UpdateFebruary 26, 2024 | markets.businessinsider.comRevive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110February 1, 2024 | markets.businessinsider.comRevive Therapeutics Explores the Use of Bucillamine for Long COVIDJanuary 31, 2024 | markets.businessinsider.comRevive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500January 24, 2024 | financialpost.comRevive Therapeutics Ltd. Announces Offering of Up to $3 MillionJanuary 16, 2024 | tmcnet.comRevive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development CanadaJanuary 10, 2024 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineJanuary 10, 2024 | markets.businessinsider.comRevive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineJanuary 8, 2024 | msn.comTravere Therapeutics expects Q4 net product sales from continuing operations to be about $40MDecember 20, 2023 | markets.businessinsider.comRevive Therapeutics Announces Results of Annual General and Special Meeting of ShareholdersDecember 18, 2023 | markets.businessinsider.comRevive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of BucillamineDecember 18, 2023 | financialpost.comRevive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of BucillamineOctober 17, 2023 | markets.businessinsider.comRevive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent ExposureOctober 17, 2023 | markets.businessinsider.comRevive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent ExposureOctober 11, 2023 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentOctober 11, 2023 | tmcnet.comRevive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentSeptember 28, 2023 | ft.comItaly turns to Kyrgyz shepherds to revive Sardinian farmingAugust 22, 2023 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation DevelopmentSee More Headlines Receive RVV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)6/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:RVV CUSIPN/A CIKN/A Webwww.revivethera.com Phone+1-905-6055535FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.14 Quick Ratio6.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.03 per share Price / Cash Flow3.18 Book ValueC$0.02 per share Price / Book4.21Miscellaneous Outstanding Shares72,411,000Free FloatN/AMarket CapC$5.79 million OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Craig Leon (Age 51)Chairman & CEO Mr. Fabio Chianelli (Age 41)Pres & Director Mr. Carmelo Marrelli C.A. (Age 48)C.P.A., CPA, B.Comm., CA, CGA, ACIS, Chief Financial Officer Key CompetitorsQuest PharmaTechCVE:QPTInnovotechCVE:IOTHemostemixCVE:HEMPacgen Life Science Co. (PBS.V)CVE:PBSMedifocus Inc. (MFS.V)CVE:MFSView All CompetitorsInsidersMichael FrankBought 150,000 shares on 3/18/2024Total: C$5,250.00 ($0.04/share)Michael FrankBought 304,000 shares on 3/15/2024Total: C$9,120.00 ($0.03/share) RVV Stock Analysis - Frequently Asked Questions How have RVV shares performed in 2024? Revive Therapeutics' stock was trading at C$0.08 at the beginning of 2024. Since then, RVV shares have increased by 0.0% and is now trading at C$0.08. View the best growth stocks for 2024 here. When is Revive Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our RVV earnings forecast. What other stocks do shareholders of Revive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revive Therapeutics investors own include Heat Biologics (HTBX), Green Organic Dutchman (TGOD), Aurora Cannabis (ACB), CytoDyn (CYDY), Genprex (GNPX), iBio (IBIO), Sorrento Therapeutics (SRNE), Workhorse Group (WKHS), Acasti Pharma (ACST) and Anavex Life Sciences (AVXL). How do I buy shares of Revive Therapeutics? Shares of RVV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:RVV) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revive Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
